Barclays Maintains an 'Overweight' on Health Management (HMA); Takeaways From Barclays Global Health Care Conference

March 20, 2012 2:27 PM EDT
Get Alerts HMA Hot Sheet
Price: $10.54 --0%

Rating Summary:
    4 Buy, 15 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Health Management (NYSE: HMA) price target of $8.00.

Analyst, Adam Feinstein, highlights included: 1) The Tennova acquisition in Knoxville is performing better than HMA had initially expected; 2) HMA has acquired $1.3 billion in revenue over the past two years, representing approximately 20% of the company's revenue, and the margin ramp at these facilities provides good visibility into EBITDA growth; 3) HMA provided some helpful clarity on their year-end cash and payables balance, which we also confirmed in our review of the company's 10-K - we believe this is a non-event with the change in cash being offset by a change on the payables line."

For an analyst ratings summary and ratings history on Health Management click here. For more ratings news on Health Management click here.

Shares of Health Management closed at $7.14 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Barclays